ROR1 and cancer: Although ROR1 could indeed serve as a promising tumor antigen with high immunogenicity, therapeutic cancer vaccines still face the challenges of overcoming cancer immunosuppression and eliciting an adequate immune response; major obstacles that have thus far resulted in disappointing results of the vaccination approach in patients.